# Adaptive COVID-19 Treatment Trial 3 (ACTT-3)

> **NCT04492475** · PHASE3 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 969 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Interferon beta-1a
- **OTHER:** Placebo
- **DRUG:** Remdesivir

## Key facts

- **NCT ID:** NCT04492475
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-05
- **Primary completion:** 2020-12-21
- **Final completion:** 2020-12-21
- **Target enrollment:** 969 (ACTUAL)
- **Last updated:** 2022-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04492475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04492475, "Adaptive COVID-19 Treatment Trial 3 (ACTT-3)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04492475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*